Breaking Finance News

Cantor Fitzgerald downgraded Bluebirdbio (NASDAQ:BLUE) from Hold to Sell in a statement released earlier today.

Yesterday Bluebirdbio (NASDAQ:BLUE) traded -0.47% lower at $65.24. BLUE’s 50-day average is $63.52 and its two hundred day average is $50.81. With the last close up 28.40% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was up over the average, with 1,584,592 shares of BLUE changing hands over the typical 1,147,150

Cantor Fitzgerald has downgraded Bluebirdbio (NASDAQ:BLUE) from Hold to Sell in a report released on 10/14/2016.

Recent Performance Chart

Bluebirdbio (NASDAQ:BLUE)

Bluebirdbio has with a one year low of $35.37 and a one year high of $99.70 and has a market capitalization of $0.

In addition to Cantor Fitzgerald reporting its target price, a total of 14 brokers have issued a report on the stock. The consensus target price is $89.07 with 6 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 3 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Bluebirdbio (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *